1016822-34-6

Basic information

• Product Name: 4-((1H-1,2,4-triazol-1-yl)methyl)-N'-hydroxybenzimidamide
• Synonyms: 4-((1H-1,2,4-triazol-1-yl)methyl)-N'-hydroxybenzimidamide
• CAS NO: 1016822-34-6
• Molecular Weight: 217.23
• Mol File: 1016822-34-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-((1H-1,2,4-triazol-1-yl)methyl)-N'-hydroxybenzimidamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-((1H-1,2,4-triazol-1-yl)methyl)-N'-hydroxybenzimidamide(1016822-34-6)
• EPA Substance Registry System: 4-((1H-1,2,4-triazol-1-yl)methyl)-N'-hydroxybenzimidamide(1016822-34-6)

Safety Data

• Hazardous Substances Data: 1016822-34-6(Hazardous Substances Data)

Upstream product

• 112809-25-3 4-((1H-1,2,4-triazole-1-yl)methyl)benzonitrile 

Downstream Products

• 1258010-22-8 3-(4-((1H-1,2,4-triazol-1-yl)methyl)phenyl)-5-(1-cyclohexyl-5-(methoxymethyl)-1H-pyrazol-4-yl)-1,2,4-oxadiazole 
• 1258009-98-1 3-(4-((1H-1,2,4-triazol-1-yl)methyl)phenyl)-5-(1-cyclohexyl-5-(pyridin-4-yl)-1H-pyrazol-4-yl)-1,2,4-oxadiazole 

Relevant articles and documents

Novel monoamine oxidase inhibitors based on the privileged 2-imidazoline molecular framework

Series of structurally diverse 2-imidazoline derivatives have been synthesized by condensation of substituted aldehydes with ethylenediamine, Pd-catalyzed N-arylation of 2-imidazolines and by the formation of 1,2,4-oxadiazoles and benzoxazepines from 2-imidazoline-containing precursors. The 2-imidazoline derivatives were evaluated as potential inhibitors of human monoamine oxidase (MAO) A and B. Among the 2-imidazolines, good potency inhibitors were discovered with compound 9p (IC50 = 0.012 μM) being the most potent MAO-B inhibitor, while compound 9d (IC50 = 0.751 μM) was the most potent MAO-A inhibitor of the series. These potencies are in the same range as those of reference MAO inhibitors used in the clinic. Among 33 compounds evaluated, 13 exhibited IC50 values in the submicromolar range for the inhibition of an MAO isoform. It is postulated that the imidazoline moieties of some of these inhibitors may be recognized by the imidazoline I2-binding site of MAO. Good potency MAO inhibitors may be useful for the treatment of neuropsychiatric and neurodegenerative disorders such as depression and Parkinson's disease, and future application for the treatment of prostate cancer, congestive heart failure and Alzheimer's disease. In addition, high potency 2-imidazoline-derived MAO inhibitors may be used as potential probes for the imidazoline binding sites of the MAOs, as well as to determine alternative binding regions of imidazoline within the MAO active site.